Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
Sebastien Guery, Munich (DE); Markus Lehtinen, Vantaa (FI); Sinikka Anneli Latvala, Helsinki (FI); Liisa Lehtoranta, Sundsberg (FI); Bryan-James Zabel, Madison, WI (US); Wesley William Morovic, Edgerton, WI (US); Charles Budinoff, Oregon, WI (US); and Scott D. Power, Woodside, CA (US)
Assigned to DUPONT NUTRITION BIOSCIENCES APS, Lyngby (DK)
Filed by DUPONT NUTRITION BIOSCIENCES APS, Copenhagen (DK)
Filed on Apr. 1, 2022, as Appl. No. 17/711,081.
Application 17/711,081 is a continuation of application No. 17/240,433, filed on Apr. 26, 2021, granted, now 11,318,174.
Claims priority of provisional application 63/140,097, filed on Jan. 21, 2021.
Claims priority of provisional application 63/107,878, filed on Oct. 30, 2020.
Claims priority of provisional application 63/050,009, filed on Jul. 9, 2020.
Claims priority of application No. 20188807 (EP), filed on Jul. 31, 2020.
Prior Publication US 2022/0370519 A1, Nov. 24, 2022
1. A method for decreasing viral load in a subject infected with SARS-CoV2 coronavirus, said method comprising administering an effective amount of a composition comprising Bifidobacterium longum subsp. infantis strain Bi-26; Bifidobacterium animalis subsp. lactis strain Bl-04; Lacticaseibacillus paracasei strain Lpc-37; Lacticaseibacillus rhamnosus strain Lr-32 and/or Ligilactobacillus salivarius strain Ls-33 to said subject infected with SARS-CoV2 coronavirus, wherein the viral load is decreased relative to the viral load in a subject that has not been treated with an effective amount of the composition.
